NASDAQ:OMER

Omeros Competitors

$18.57
-0.56 (-2.93 %)
(As of 04/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$18.20
Now: $18.57
$19.21
50-Day Range
$16.93
MA: $18.72
$19.95
52-Week Range
$9.25
Now: $18.57
$25.46
Volume535,711 shs
Average Volume725,516 shs
Market Capitalization$1.15 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.65

Competitors

Omeros (NASDAQ:OMER) Vs. JNJ, PFE, MRK, ABBV, LLY, and BMY

Should you be buying OMER stock or one of its competitors? Companies in the sub-industry of "pharmaceuticals" are considered alternatives and competitors to Omeros, including Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), AbbVie (ABBV), Eli Lilly and (LLY), and Bristol-Myers Squibb (BMY).

Omeros (NASDAQ:OMER) and Johnson & Johnson (NYSE:JNJ) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, risk, valuation, institutional ownership and dividends.

Analyst Recommendations

This is a summary of current recommendations and price targets for Omeros and Johnson & Johnson, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Omeros02402.67
Johnson & Johnson031102.79

Omeros currently has a consensus price target of $23.40, indicating a potential upside of 26.01%. Johnson & Johnson has a consensus price target of $183.25, indicating a potential upside of 10.94%. Given Omeros' higher probable upside, research analysts clearly believe Omeros is more favorable than Johnson & Johnson.

Volatility & Risk

Omeros has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500.

Insider & Institutional Ownership

56.6% of Omeros shares are owned by institutional investors. Comparatively, 67.3% of Johnson & Johnson shares are owned by institutional investors. 11.3% of Omeros shares are owned by company insiders. Comparatively, 0.3% of Johnson & Johnson shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Omeros and Johnson & Johnson's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Omeros$111.81 million10.29$-84,490,000.00($0.96)-19.34
Johnson & Johnson$82.06 billion5.30$15.12 billion$8.6819.03

Johnson & Johnson has higher revenue and earnings than Omeros. Omeros is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Omeros and Johnson & Johnson's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Omeros-134.59%N/A-59.49%
Johnson & Johnson21.01%34.64%13.40%

Summary

Johnson & Johnson beats Omeros on 10 of the 14 factors compared between the two stocks.

Omeros (NASDAQ:OMER) and Pfizer (NYSE:PFE) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, institutional ownership, dividends and earnings.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Omeros and Pfizer, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Omeros02402.67
Pfizer010302.23

Omeros presently has a consensus target price of $23.40, indicating a potential upside of 26.01%. Pfizer has a consensus target price of $38.5714, indicating a potential downside of 0.18%. Given Omeros' stronger consensus rating and higher probable upside, research analysts plainly believe Omeros is more favorable than Pfizer.

Insider and Institutional Ownership

56.6% of Omeros shares are held by institutional investors. Comparatively, 67.4% of Pfizer shares are held by institutional investors. 11.3% of Omeros shares are held by insiders. Comparatively, 0.1% of Pfizer shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Omeros and Pfizer's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Omeros$111.81 million10.29$-84,490,000.00($0.96)-19.34
Pfizer$51.75 billion4.16$16.27 billion$2.9513.10

Pfizer has higher revenue and earnings than Omeros. Omeros is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Omeros has a beta of 1.65, suggesting that its share price is 65% more volatile than the S&P 500. Comparatively, Pfizer has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500.

Profitability

This table compares Omeros and Pfizer's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Omeros-134.59%N/A-59.49%
Pfizer17.85%24.88%9.32%

Summary

Pfizer beats Omeros on 8 of the 14 factors compared between the two stocks.

Merck & Co., Inc. (NYSE:MRK) and Omeros (NASDAQ:OMER) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations and dividends.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Merck & Co., Inc. and Omeros, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Merck & Co., Inc.021102.85
Omeros02402.67

Merck & Co., Inc. presently has a consensus price target of $96.2727, indicating a potential upside of 23.49%. Omeros has a consensus price target of $23.40, indicating a potential upside of 26.01%. Given Omeros' higher possible upside, analysts clearly believe Omeros is more favorable than Merck & Co., Inc..

Profitability

This table compares Merck & Co., Inc. and Omeros' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Merck & Co., Inc.24.33%53.83%16.83%
Omeros-134.59%N/A-59.49%

Valuation and Earnings

This table compares Merck & Co., Inc. and Omeros' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Merck & Co., Inc.$46.84 billion4.21$9.84 billion$5.1915.02
Omeros$111.81 million10.29$-84,490,000.00($0.96)-19.34

Merck & Co., Inc. has higher revenue and earnings than Omeros. Omeros is trading at a lower price-to-earnings ratio than Merck & Co., Inc., indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Merck & Co., Inc. has a beta of 0.43, meaning that its stock price is 57% less volatile than the S&P 500. Comparatively, Omeros has a beta of 1.65, meaning that its stock price is 65% more volatile than the S&P 500.

Insider & Institutional Ownership

72.9% of Merck & Co., Inc. shares are held by institutional investors. Comparatively, 56.6% of Omeros shares are held by institutional investors. 0.3% of Merck & Co., Inc. shares are held by company insiders. Comparatively, 11.3% of Omeros shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Merck & Co., Inc. beats Omeros on 10 of the 14 factors compared between the two stocks.

AbbVie (NYSE:ABBV) and Omeros (NASDAQ:OMER) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, valuation, profitability, analyst recommendations, risk, dividends and earnings.

Risk & Volatility

AbbVie has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500. Comparatively, Omeros has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500.

Profitability

This table compares AbbVie and Omeros' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AbbVie18.16%439.24%13.22%
Omeros-134.59%N/A-59.49%

Earnings and Valuation

This table compares AbbVie and Omeros' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbbVie$33.27 billion5.84$7.88 billion$8.9412.31
Omeros$111.81 million10.29$-84,490,000.00($0.96)-19.34

AbbVie has higher revenue and earnings than Omeros. Omeros is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

67.5% of AbbVie shares are held by institutional investors. Comparatively, 56.6% of Omeros shares are held by institutional investors. 0.1% of AbbVie shares are held by company insiders. Comparatively, 11.3% of Omeros shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings for AbbVie and Omeros, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AbbVie121302.75
Omeros02402.67

AbbVie presently has a consensus price target of $115.75, indicating a potential upside of 5.18%. Omeros has a consensus price target of $23.40, indicating a potential upside of 26.01%. Given Omeros' higher possible upside, analysts plainly believe Omeros is more favorable than AbbVie.

Summary

AbbVie beats Omeros on 10 of the 14 factors compared between the two stocks.

Omeros (NASDAQ:OMER) and Eli Lilly and (NYSE:LLY) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, risk, dividends, earnings and institutional ownership.

Analyst Recommendations

This is a summary of current ratings and target prices for Omeros and Eli Lilly and, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Omeros02402.67
Eli Lilly and031102.79

Omeros currently has a consensus target price of $23.40, suggesting a potential upside of 26.01%. Eli Lilly and has a consensus target price of $199.1429, suggesting a potential upside of 6.47%. Given Omeros' higher possible upside, equities analysts plainly believe Omeros is more favorable than Eli Lilly and.

Institutional & Insider Ownership

56.6% of Omeros shares are owned by institutional investors. Comparatively, 75.6% of Eli Lilly and shares are owned by institutional investors. 11.3% of Omeros shares are owned by insiders. Comparatively, 0.1% of Eli Lilly and shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Omeros and Eli Lilly and's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Omeros-134.59%N/A-59.49%
Eli Lilly and24.01%166.45%15.18%

Valuation and Earnings

This table compares Omeros and Eli Lilly and's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Omeros$111.81 million10.29$-84,490,000.00($0.96)-19.34
Eli Lilly and$22.32 billion8.04$8.32 billion$6.0430.97

Eli Lilly and has higher revenue and earnings than Omeros. Omeros is trading at a lower price-to-earnings ratio than Eli Lilly and, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Omeros has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500. Comparatively, Eli Lilly and has a beta of 0.37, indicating that its share price is 63% less volatile than the S&P 500.

Summary

Eli Lilly and beats Omeros on 10 of the 14 factors compared between the two stocks.

Bristol-Myers Squibb (NYSE:BMY) and Omeros (NASDAQ:OMER) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Earnings & Valuation

This table compares Bristol-Myers Squibb and Omeros' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bristol-Myers Squibb$26.15 billion5.67$3.44 billion$4.6914.14
Omeros$111.81 million10.29$-84,490,000.00($0.96)-19.34

Bristol-Myers Squibb has higher revenue and earnings than Omeros. Omeros is trading at a lower price-to-earnings ratio than Bristol-Myers Squibb, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Bristol-Myers Squibb and Omeros, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bristol-Myers Squibb021312.94
Omeros02402.67

Bristol-Myers Squibb currently has a consensus target price of $74.60, suggesting a potential upside of 12.48%. Omeros has a consensus target price of $23.40, suggesting a potential upside of 26.01%. Given Omeros' higher possible upside, analysts clearly believe Omeros is more favorable than Bristol-Myers Squibb.

Institutional and Insider Ownership

72.4% of Bristol-Myers Squibb shares are held by institutional investors. Comparatively, 56.6% of Omeros shares are held by institutional investors. 0.1% of Bristol-Myers Squibb shares are held by insiders. Comparatively, 11.3% of Omeros shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Bristol-Myers Squibb and Omeros' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bristol-Myers Squibb-0.11%27.48%10.77%
Omeros-134.59%N/A-59.49%

Volatility and Risk

Bristol-Myers Squibb has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500. Comparatively, Omeros has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500.

Summary

Bristol-Myers Squibb beats Omeros on 10 of the 15 factors compared between the two stocks.


Omeros Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Johnson & Johnson logo
JNJ
Johnson & Johnson
2.7$165.18-0.9%$434.87 billion$82.06 billion25.97Earnings Announcement
Dividend Increase
Analyst Revision
Pfizer logo
PFE
Pfizer
2.1$38.64-2.3%$215.52 billion$51.75 billion24.93Dividend Announcement
Merck & Co., Inc. logo
MRK
Merck & Co., Inc.
2.2$77.96-1.6%$197.27 billion$46.84 billion17.25Upcoming Earnings
AbbVie logo
ABBV
AbbVie
2.8$110.05-0.7%$194.22 billion$33.27 billion23.27Upcoming Earnings
Analyst Revision
Eli Lilly and logo
LLY
Eli Lilly and
2.1$187.05-2.1%$179.38 billion$22.32 billion30.56Upcoming Earnings
Bristol-Myers Squibb logo
BMY
Bristol-Myers Squibb
2.3$66.32-0.0%$148.15 billion$26.15 billion-602.85Upcoming Earnings
Analyst Revision
Zoetis logo
ZTS
Zoetis
1.8$169.07-0.6%$80.31 billion$6.26 billion50.17Ex-Dividend
Insider Selling
News Coverage
Royalty Pharma logo
RPRX
Royalty Pharma
1.7$43.21-1.0%$26.23 billionN/A0.00
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.4$94.15-0.6%$21.10 billion$1.30 billion25.72
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.1$167.52-1.4%$9.44 billion$2.16 billion52.85Analyst Report
Analyst Revision
Perrigo logo
PRGO
Perrigo
2.3$42.63-0.2%$5.69 billion$4.84 billion-710.38Upcoming Earnings
Dividend Announcement
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$20.10-1.8%$3.66 billion$114.62 million-8.10
Pacira BioSciences logo
PCRX
Pacira BioSciences
1.9$64.45-1.0%$2.83 billion$421.03 million22.69
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.5$23.88-2.9%$2.80 billion$306.49 million26.83
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.7$31.30-0.3%$1.66 billion$392.76 million12.99
Endo International logo
ENDP
Endo International
1.5$5.90-1.2%$1.36 billion$2.91 billion-8.68Gap Down
Zogenix logo
ZGNX
Zogenix
1.7$18.94-0.1%$1.06 billion$3.65 million-1.99Analyst Upgrade
News Coverage
Paratek Pharmaceuticals logo
PRTK
Paratek Pharmaceuticals
1.5$7.87-1.9%$369.05 million$16.54 million-3.20
BioDelivery Sciences International logo
BDSI
BioDelivery Sciences International
2.1$3.49-2.0%$352.01 million$111.39 million24.93News Coverage
Lannett logo
LCI
Lannett
2.0$5.01-2.2%$207.42 million$545.74 million-6.96News Coverage
Assembly Biosciences logo
ASMB
Assembly Biosciences
1.6$4.37-6.2%$175.06 million$15.96 million-2.65
Cumberland Pharmaceuticals logo
CPIX
Cumberland Pharmaceuticals
0.9$2.96-2.7%$44.17 million$47.53 million-13.45
This page was last updated on 4/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.